T3
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Direct thyroid-hormone replacement for users who need active T3 rather than more T4; a high-leverage fat-loss accelerator only when the user accepts thyroid suppression, cardiac monitoring, and muscle-protection requirements.
T3 is not a casual fat burner: heart rate/rhythm, thyroid labs, muscle protection, adrenal vulnerability, bone risk, and dose verification define the safety boundary.
Direct thyroid-hormone replacement for users who need active T3 rather than more T4; a high-leverage fat-loss accelerator only when the user accepts thyroid suppression, cardiac monitoring, and muscle-protection requirements. The practical split is important: therapeutic T3 is a deficiency-correction tool, while performance-dose T3 is a metabolic overdrive drug.
Risk is dose- and context-dependent. Therapeutic liothyronine in deficient patients has a much cleaner safety profile than performance dosing, but supraphysiologic use can produce tachycardia, palpitations, arrhythmia risk, rapid muscle loss without AAS, connective-tissue catabolism, bone loss over chronic exposure, and a cortisol/adrenal crash in vulnerable users.
T3 is useful because it is already the active thyroid signal. It bypasses the T4-to-T3 conversion bottleneck that leaves some hypothyroid patients symptomatic despite normal-looking TSH, and it gives performance users a direct way to raise metabolic rate. That same directness is why it is unforgiving: product authenticity, heart rate, body temperature, thyroid labs, and muscle-sparing context decide whether the upside is worth it.
High when the substrate is right: true low-T3 state, impaired conversion, reverse-T3 dominance, or deliberately suppressed thyroid output during a monitored cut. Much less compelling as a casual add-on for healthy euthyroid users, where the article's own evidence and community posture both point toward added burden without guaranteed extra benefit.
Intro
T3 (triiodothyronine, liothyronine) is the biologically active thyroid hormone. T4 (thyroxine/levothyroxine) is a prohormone that must be converted to T3 by deiodinase enzymes in peripheral tissues before exerting most of its effects. Pharmaceutical T3 — sold as liothyronine sodium — has been FDA-approved since the 1950s for hypothyroidism. T3 use bifurcates sharply into two populations with essentially no overlap in dose, intent, or risk profile. The patient population uses 5–40 mcg/day to correct a real deficiency where TSH is normal but Free T3 is chronically low despite T4 supplementation; the performance population uses roughly 25–100 mcg/day to create a supraphysiologic metabolic state during contest-prep cutting, virtually always with concurrent anabolic steroids. A smaller metabolic-optimization lane uses 1–10 mcg 2–3x daily as a general health intervention, far below either clinical or performance ranges. T3's legitimacy as a medicine is supported by substantial clinical evidence: a 2024 meta-analysis of LT3 safety across 630,254 patients found no increased risk of atrial fibrillation, heart failure, or stroke at regulated doses, and a large cohort study showed reduced all-cause mortality (RR 0.70) in LT3 users vs T4-only users. That clinical safety signal should not be carried over to unregulated high-dose performance use. Serious adverse events in the clinical literature concentrate around unregulated use, pharmacy compounding errors, deliberate overdose, or vulnerable physiology rather than regulated therapeutic liothyronine.
Observed Effects
T3 raises resting metabolic rate proportionally to dose. At 75 mcg/day for 14 days, Free T3 increases approximately 1.7-fold and RMR increases approximately 15%.
Community first-person reports consistently document 0.5–1 kg/week fat loss at 50 mcg/day during caloric restriction. The mechanism is thermal: UCP-driven mitochondrial uncoupling increases heat generation, burning calories as heat rather than storing as fat. Body temperature elevation (subjectively felt as warmth and sweating) is a reliable proxy for metabolic rate elevation. For genuinely hypothyroid patients, T3 supplementation produces quality-of-life improvements that T4 monotherapy frequently fails to deliver — mood and mental clarity improvement within hours of first dose, weight loss without intentional restriction, reduced hair loss, improved sleep quality. The 2024 BMC meta-analysis confirmed combination T4+T3 improved GHQ-28 general health scores (MD -2.89, 95% CI -3.16 to -2.63) vs T4 monotherapy. T3 increases hepatic LDL receptor expression, producing dramatic lipid normalization in hypothyroid patients: documented first-person reports show total cholesterol from 334 mg/dL to normal and LDL from 238 mg/dL to normal within 1 month of 50 mcg supplementation. In adult cardiac surgery patients with post-bypass low-T3 state, T3 infusion improved cardiac index by 0.24 L/min/m2 (95% CI 0.08–0.40) in a 2022 meta-analysis — but this effect is population-specific and requires an underlying T3 deficiency state. In euthyroid subjects, supraphysiologic T3 failed to produce measurable benefit (sheep model: 8x normal fT3, 45 endpoints measured, no significant response), confirming that T3's dramatic metabolic effects require a T3-deficient or TSH-suppressed substrate.
Field Reports
Patient first-person accounts are consistently dramatic for genuinely hypothyroid individuals. A representative account: Cytomel 25 mcg week 1 → 50 mcg week 2 resulted in lipid normalization (total cholesterol 334 → normal, LDL 238 → normal) within 1 month, with energy described as 'like a new person.' A second account documents weight drop from 69 to 67.3 kg in 2 weeks without exercise on 1,500–1,700 calories/day — 'I haven't weighed less than 68 kg in three years' — with mood dramatically improved within hours of first dose, reduced hair loss, and shorter lighter periods. Common patient side effects: constipation (sometimes severe), palpitations at higher doses, anxiety if dose escalated too fast. Bodybuilding first-person reports split along the AAS line with consistent clarity: with concurrent AAS, users describe 'best physique ever,' dramatic fat loss, maintained muscle, improved vascularity. Without AAS: near-universal reports of muscle loss, flat look, strength decline within 2–3 weeks at any dose above 25 mcg. A recurring patient experience involves T3 introduction triggering symptoms (palpitations, tinnitus, nausea, sweating, mood deterioration) that turn out to be signs of relative cortisol deficiency unmasked by T3's cortisol-accelerating metabolism — not thyroid overmedication. Resolution requires co-titrating hydrocortisone alongside T3. A notable edge case: thyroid hormone resistance users require 80–100+ mcg/day T3 with serum Free T3 above the normal range yet no clinical hyperthyroid symptoms (normal resting HR, below-normal basal temperature) — demonstrating that serum T3 is not a reliable proxy for cellular T3 activity in resistance populations. A controlled N=1 sublingual vs swallowed experiment documented Free T3 and Free T4 dropping 20–30 points through reference range after 9 weeks of switching from sublingual to swallowed tablets, confirming sublingual administration is more bioavailable for some users.
Community Consensus
T3 use is defined by a clean bifurcation between two non-overlapping populations. The patient community frames T3 self-sourcing as a workaround for T4-only care: many people with diagnosed hypothyroidism and normalized TSH on levothyroxine remain symptomatic and describe T3 access as the missing variable. The 2024 BMC meta-analysis supports the core complaint without making T3 universally superior: combination T4+T3 improved patient-reported general-health scores even when TSH looked controlled on T4 alone. The physique community treats T3 as a cornerstone cutting drug with a different risk calculus. Mandatory AAS co-administration, gradual ramp/tapering, HR/temperature monitoring, and product-verification bloodwork are the community's harm-reduction layer; none of that belongs in the patient protocol. Practitioner consensus is not uniformly bullish at performance doses. The strongest favorable posture is bullish but bounded: T3 can work powerfully for fat loss, but only when the user can protect lean tissue, verify the product, monitor cardiac load, and accept thyroid suppression. The skeptical performance take is clearest in GH-using euthyroid bodybuilders, where GH may already increase local T3 signaling and exogenous T3 can add type IIA fiber catabolism without proportional fat-loss benefit. Product authentication is a recurring consensus point: counterfeit or underdosed T3 is common enough that TSH + Free T4 suppression at 50 mcg/day functions as practical QC rather than trivia. A smaller metabolic-optimization community uses very low-dose T3 as a general metabolic signal, distinct from both hypothyroid correction and contest-prep dosing.
Risks & Monitoring
The primary safety concern at any dose above physiological replacement is cardiac risk. T3's TRalpha-mediated cardiac effects are dose-dependent: tachycardia (begins around 50 mcg/day in sensitive users), palpitations, arrhythmia risk at 100+ mcg/day. The 2024 LT3 safety meta-analysis (n=630,254) found regulated use had no increased risk of AF, heart failure, or stroke. Serious cardiac events occur primarily with unregulated use, compounding errors, or overdose. The most practically significant adverse effect for performance users is muscle catabolism. T3 at bodybuilding doses (50+ mcg/day) is non-discriminately catabolic: it burns fat AND muscle protein. Type IIA hypertrophy-responsive fibers are preferentially degraded — at 75 mcg/day for 14 days, these fibers are targeted selectively. Community consensus is absolute: T3 without concurrent AAS produces visible muscle loss and strength decline within 2–3 weeks. Supraphysiologic T3 also degrades collagen and connective tissue matrix, creating pharmacological antagonism with tissue-repair peptides like BPC-157 and TB-500 whose mechanisms depend on connective tissue angiogenesis and collagen synthesis. Severe constipation is a frequently reported side effect at bodybuilding doses (30–75 mcg/day) — documented as severe enough to prevent standing, requiring potassium, apple cider vinegar, and high water intake to resolve. Users with pre-existing low cortisol states cannot tolerate T3 introduction without concurrent cortisol support. Multiple patient reports document severe adverse effects (suicidal ideation, palpitations, tinnitus, nausea, sweating) upon T3 introduction that resolved only when hydrocortisone was co-titrated. T3 also raises hepatic SHBG synthesis, reducing free testosterone and free estrogen fractions — relevant for natural male athletes where this can meaningfully reduce free T.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establish baseline thyroid axis function before starting. TSH alone is inadequate — Free T3 is the most important monitoring marker. Reverse T3 should be added at baseline if rT3 dominance is suspected as the indication for T3 therapy.
Retest every 6–8 weeks during titration. Expected: TSH suppression (acceptable at therapeutic doses), Free T4 decline. At 50 mcg/day genuine T3 should suppress TSH to <0.07 mU/L AND drive Free T4 below measurable limits — if it doesn't, product may be underdosed or counterfeit.
Elevated rT3 relative to Free T3 is one of the strongest indicators for T3 supplementation. If rT3 dominance is the suspected diagnosis, include at baseline and monitor for normalization during the rT3 clearing protocol.
Heart rate above 80 bpm at rest is the primary dose-ceiling indicator during titration. Persistent resting HR elevation signals dose is too high — reduce by 5–12.5 mcg and recheck over 3–5 days.
Oral temperature before rising each morning is the most practical titration endpoint. Target: 98.6°F (37°C). Below target = underdosed or poor conversion. Above 98.7°F = overdosed. Temperature trend guides dose adjustments more reliably than lab values during titration.
Hypothyroid patients frequently present with elevated total cholesterol and LDL. T3 normalization dramatically improves lipid profiles via LDL receptor upregulation. Baseline documents pre-treatment state; follow-up at 4–8 weeks confirms response.
Iron deficiency impairs T3 absorption. Ferritin deficiency is common in hypothyroid women and creates pooling — inadequate tissue uptake despite normal serum T3. Iron and T3 must be separated by 4+ hours in dosing schedule.
Low cortisol states are incompatible with T3 introduction in sensitive patients. T3 accelerates cortisol clearance — inadequate adrenal reserve can create a relative cortisol deficiency crisis on T3 introduction. Check if fatigue, low blood pressure, salt cravings, or history of chronic illness.
Avoid With
Do not combine T3 with the following. Sorted highest-severity first.
Why:T3 upregulates beta-adrenergic receptor density; clenbuterol is a beta-2 agonist. The combination creates multiplicative (not additive) cardiovascular burden — massively amplified sympathomimetic load. Associated with cardiac events in bodybuilder mortality discussions in the practitioner-educator community.
What to do:This combination is widely used in bodybuilding cutting stacks but widely flagged as dangerous. If both compounds are used, cardiac monitoring is mandatory, any existing cardiac conditions are absolute contraindication, and doses should be the minimum effective for each compound. Blood pressure and heart rate must be actively tracked.
Why:Supraphysiologic T3 catabolizes connective tissue collagen and matrix — pharmacologically opposing BPC-157's and TB-500's mechanisms of angiogenesis-driven connective tissue repair. The counter-current of T3 catabolism reduces the efficacy of tissue-repair peptides.
What to do:Documented in practitioner-educator community discourse but lacking formal clinical evidence. Practical implication: if running T3 for cutting while healing an injury with BPC-157 or TB-500, keep T3 dose as low as possible and minimize for the duration of active tissue repair.
Why:Growth hormone increases T4-to-T3 peripheral conversion via D2 deiodinase upregulation in liver, muscle, and brain. Healthy GH users may already have elevated tissue T3 — adding exogenous T3 may not increase fat burning proportionally but does add dose-dependent type IIA muscle catabolism.
What to do:Mechanistic analysis: exogenous GH cannot cause central hypothyroidism but may reveal pre-existing thyroid conditions. For healthy GH users without thyroid issues, T3 supplementation is arguably redundant. For GH users who are hypothyroid or have impaired conversion, the calculation is different and T3 addition is warranted.
Why:Iron chelates oral T3 in the gut, significantly impairing absorption. One of the most significant drug-supplement interactions for T3 users.
What to do:Separate T3 and iron supplementation by 4+ hours. Same separation applies to calcium carbonate and magnesium supplements. Especially relevant for hypothyroid women who commonly co-supplement iron for ferritin deficiency.
Protocols By Goal
Hypothyroid correction: observed patient protocols start low, titrate by body temperature and symptoms rather than TSH alone, and retest a full panel every 6-8 weeks.
Cofactor repletion is central: selenium for deiodinase activity, zinc for thyroid synthesis, iron for absorption, iodine if deficient, and magnesium for general metabolic support. Free T3 is the primary monitoring marker; Reverse T3 is the strongest indicator for T3 therapy; TSH is a poor guide for T3-only dosing.
Contest prep fat loss: observed physique protocols use a diamond ramp over 8-10 weeks and pair T3 with an anabolic base to reduce severe muscle loss. Some male protocols mention testosterone plus Anavar, but this adds meaningful androgenic risk and should not be generalized to women. Protein intake is usually kept high, and users avoid running T3 late into prep after lean mass is already depleted because Type IIA fiber catabolism is most damaging when the user is already in a catabolic state from caloric restriction. Lab verification is used to avoid escalating on counterfeit or underdosed product.
rT3 clearing: moderate-dose T3 protocols for 8-12 weeks are reported with full panel monitoring every 6 weeks and tapering after rT3 normalizes. The original driver (chronic illness, caloric restriction, medication, inflammation) still has to be addressed or rT3 will reaccumulate.
Very-low-dose metabolic optimization: 1-3 mcg 2-3x daily is a separate niche. Seasonal adjustment is sometimes reported. The goal is metabolic substrate stabilization, not fat loss or deficiency correction.
Dosing Details
Hypothyroid patient protocols usually begin at very low doses, often 2.5-5 mcg/day in sensitive, ME/CFS, adrenal, or T3-naive patients, then move slowly by symptoms, resting heart rate, basal temperature, and full thyroid labs rather than TSH alone. Lab retesting every 6-8 weeks commonly includes Free T3, Free T4, Reverse T3, and TSH. TSH suppression can be expected on T3 and is not automatically a stopping criterion. Most patient reports cluster between 25-60 mcg/day, while thyroid hormone resistance outliers may require much higher supervised doses.
Bodybuilding reports use a separate and higher-risk diamond ramp/taper pattern, often moving from 25 mcg toward 75-100 mcg before tapering back down over 8-10 weeks. The community rationale is that ramping reduces acute sympathetic shock and tapering reduces metabolic rebound. These reports almost always pair performance-dose T3 with an anabolic base because T3 without anabolic protection is repeatedly associated with severe muscle loss within 2-3 weeks. This is not a recommendation for AAS use; it is the reason performance-dose T3 is a poor standalone cutting tool and especially unattractive for women.
High reverse T3 clearing protocols are described around moderate T3 doses for 8-12 weeks with full panel monitoring until rT3 normalizes, then tapering. The underlying driver — chronic illness, caloric restriction, medication, inflammation — still has to be addressed or rT3 can reaccumulate.
Wilson-style cycling protocols use slow-release T3 with oral temperature tracking before rising and taper off after temperature stabilizes. This is a distinct therapeutic school rather than bodybuilding practice.
Dosing schedule: split doses (2-3x daily) are used to reduce cardiovascular peaks and arrhythmia risk at higher doses. Single daily bedtime dosing aligns with the nocturnal TSH spike and is used in some therapeutic protocols. Both approaches are in active community use.
Stacks & Alternatives
Minimum required co-compound at bodybuilding doses. T3 at 25–75 mcg/day requires at minimum 200–250 mg testosterone/week to offset muscle catabolism. Testosterone suppresses SHBG (offsetting T3's SHBG-elevating effect) and provides direct anabolic stimulus to prevent T3-driven protein catabolism.
Consistently cited as the perfect T3-stacking anabolic for contest prep. Low androgenicity, direct muscle-sparing mechanism (increases intramuscular phosphocreatine, enhances fat oxidation), strength preservation during caloric restriction. T3 50–75 mcg + test 200–300 mg/week + Anavar 40–80 mg/day is the archetypal contest cutting stack.
Standard combination therapy for hypothyroid patients who don't respond adequately to T4 monotherapy. T4 provides stable long-half-life substrate that converts peripherally; T3 provides direct active hormone signal. Target ratio approximately LT4:LT3 15:1 per guidelines, though clinical evidence supports ratios as low as 4:1 without safety signals.
Advanced full anabolic stack. GH drives IGF-1 and lipolysis while also increasing T4-to-T3 conversion via D2 deiodinase upregulation. In healthy GH users, T3 addition may be redundant (GH already elevates tissue T3). In GH users with hypothyroidism or impaired conversion, explicit T3 addition is warranted. Insulin is often added as the fourth component (anabolic shuttle).
An alternative to standalone T3, providing a fixed T4+T3 combination (approximately 38 mcg T4 + 9 mcg T3 per grain). Preferred by functional/integrative practitioners and many patient communities over synthetic T3 alone because it provides both hormone forms. The Armour ratio (~4:1 T4:T3) is more T3-heavy than standard combination prescriptions.
Alternatives
Stack Cost
A moderate-tax add-on compound requiring mandatory concurrent AAS at performance doses and daily HR/temperature monitoring — not a standalone compound and not appropriate as a first performance compound.
Daily resting heart rate and basal body temperature monitoring required throughout use. Full thyroid panel (Free T3, Free T4, rT3, TSH) every 6–8 weeks. Lab verification is especially important when product quality is uncertain. Cannot be used without a monitoring protocol.
T3 suppresses the HPT axis by reducing TSH and endogenous T4 production via negative feedback. Gradual taper required after performance-dose use to allow HPT axis recovery. Abrupt cessation from 100 mcg produces metabolic rebound. Recovery typically 4–6 weeks post-taper.
Mandatory concurrent AAS at bodybuilding doses — T3 without testosterone produces severe muscle catabolism within 2–3 weeks. Hard contraindication with clenbuterol co-stack without cardiac monitoring. Conflict with BPC-157 and TB-500 via connective tissue catabolism.
- ·Cannot be treated as a standalone performance compound; the usual anabolic-protection layer adds major androgen risk and makes this especially unattractive for women.
- ·At 75+ mcg/day, type IIA muscle fiber catabolism is significant — AAS dose must scale upward with T3 dose
- ·Stack complexity increases linearly with T3 dose — 25 mcg needs minimal support, 100 mcg needs full AAS stack plus monitoring
- ·Concurrent testosterone base (required at performance doses)
- ·Potassium supplementation if constipation develops at higher doses
- ·Hydrocortisone co-titration if adrenal compromise is present
Performance use requires managing T3 simultaneously with mandatory concurrent AAS — a first-time user would need to manage two compounds plus monitoring protocols. For hypothyroid patients under medical supervision: appropriate at low doses (5–10 mcg) with guidance. Performance use: intermediate minimum, should have prior AAS experience.
- ·No prior AAS experience and intending to use at performance doses
- ·Cardiovascular condition or existing arrhythmia history
- ·Pre-existing cortisol deficiency or adrenal fatigue (requires medical co-management)
- ·Unable to access regular bloodwork for dose verification
Gradual taper is required but straightforward when planned. Mirror the ramp-up on the way down. From 100 mcg peak: 75→50→25 mcg over 3 weeks, optional 12.5 mcg final week. HPT axis typically recovers within 4–6 weeks post-taper. Abrupt stopping from high doses produces metabolic rebound.
- ·Metabolic rebound (reduced BMR, temporary weight gain) if stopped abruptly rather than tapered
- ·Extended HPT axis recovery time if multiple long cycles have been run
- ·Women with borderline hypothyroidism may require extended monitoring after discontinuation
Ensure testosterone base minimum 200–300 mg/week before starting T3 at performance doses. Add Anavar if more muscle protection needed. If muscle loss proceeds despite AAS, the T3 dose may be disproportionately high relative to the anabolic dose — reduce T3 or increase AAS.
Run product authentication bloodwork at 4 weeks: at 50 mcg/day, genuine T3 suppresses TSH to <0.07 mU/L AND tanks Free T4 below measurable limits. If neither endpoint is met, the product is counterfeit. If only TSH is suppressed but T4 is not below range, the product is underdosed.
Check morning cortisol before starting T3 if history of chronic fatigue, low blood pressure, or salt cravings is present. If adverse effects appear on T3 introduction, do not interpret as thyroid overmedication — check adrenal status and consider co-titrating hydrocortisone (15–22.5 mg/day) alongside T3.
Keep T3 timing consistent and separate it from major absorption blockers. Iron is usually separated by 4+ hours; calcium carbonate and magnesium are also separated in careful protocols. Sublingual use is reported as more bioavailable for some users but is not a substitute for lab-guided dosing.
TRalpha-mediated cardiac stimulation increasing pacemaker current — dose-dependent and may progress to arrhythmia if not addressed
Early sign of cardiac overload from T3 — can progress to atrial fibrillation at sustained high doses
T3's TRalpha-mediated cardiac effects are dose-dependent and unpredictable in individuals with pre-existing structural or electrical cardiac issues
Multiplicative (not additive) cardiovascular burden from T3 beta-receptor upregulation + clenbuterol beta-2 agonism — associated with cardiac events in bodybuilding community
Practical Setup
Conservative initiation is a shared theme across patient and performance reports. The first dose of T3 in a hypothyroid or T3-naive user can hit the hardest because adrenaline sensitivity is elevated in the T3-deficient state and moderates over 2-3 days as T3 restores glycogen and reduces sympathetic tone. Do not interpret the first-dose reaction as the chronic dose response. Resting heart rate and basal body temperature are the two mandatory daily monitoring parameters at any dose above 25 mcg. Heart rate above 80 bpm at rest signals dose too high. Temperature persistently below 97.8°F signals dose too low. Product authentication: at 50 mcg/day genuine T3 should suppress TSH to <0.07 mU/L AND drive Free T4 below measurable limits (<5.1 pmol/L). Both endpoints must be met — meeting only one suggests partial activity; meeting neither suggests counterfeit. Absorption is fragile: food, iron, calcium carbonate, magnesium, and antacids can reduce exposure, so timing consistency matters. Tapering matters after bodybuilding doses; abrupt cessation from high-dose use can produce metabolic rebound. Storage is straightforward for regulated tablets but less reliable for liquid preparations. Women-specific: ferritin and morning cortisol are especially relevant because peri/post-menopausal women commonly have concurrent iron deficiency and adrenal compromise that must be addressed for T3 to work effectively.
Mechanism Deep Dive
T3 binds nuclear thyroid hormone receptors TRalpha and TRbeta. These receptors form heterodimers with retinoid X receptors (RXR) and regulate transcription of thyroid hormone response element-bearing genes.
TRalpha predominance in cardiomyocytes drives cardiac effects: upregulates alpha-myosin heavy chain, increases SERCA2a expression (faster calcium cycling), increases sinoatrial pacemaker current If — hence T3's dose-dependent chronotropic and inotropic effects. TRbeta predominance in liver, pituitary, and cochlea governs metabolic and lipid effects: induces UCP1 in brown adipose and UCP2/UCP3 in skeletal muscle (thermogenesis and mitochondrial uncoupling), increases LDL receptor expression in liver (cholesterol clearance), upregulates lipase expression. T3 also directly stimulates mitochondrial biogenesis via NRF1 and TFAM transcription factors — the mechanism behind fat-loss-associated metabolic rate increases. Non-genomic T3 effects operate within seconds to minutes via integrin alphavbeta3 receptor signaling (MAPK/ERK), PI3K/Akt activation, and direct mitochondrial binding — explaining the near-immediate cardiovascular impact before gene transcription changes can account for it. Lipolysis mechanism: T3 increases beta-adrenergic receptor expression in adipose tissue, amplifying catecholamine-driven lipolysis — this is why T3 + clenbuterol creates multiplicative rather than additive cardiovascular burden. HPT axis feedback: exogenous T3 suppresses TRH and TSH via negative feedback, reducing endogenous T4 secretion. T3 suppresses TSH less efficiently than T4 at equivalent doses — T4 is converted locally in the pituitary by D2 deiodinase to T3, creating a strong local TSH suppression signal; exogenous T3 bypasses this step. The body prioritizes maintaining plasma T3 in a narrow range: when T4 falls, peripheral D2 upregulates to maintain T3 — this homeostatic buffering explains why mild T4 deficiency may not manifest as T3 deficiency, and why supraphysiologic bodybuilding doses represent a genuine pharmacological departure. T3 also raises SHBG through hepatic stimulation, reducing free testosterone and estrogen fractions. At supraphysiologic doses the catabolic mechanism is dose-dependent and tissue-selective: T3 activates osteoclasts via RANKL upregulation (bone), increases nitrogen excretion (muscle protein catabolism), and breaks down collagen matrix (connective tissue). Type IIA muscle fibers are preferentially degraded at bodybuilding doses — these are the hypertrophy-responsive fast-twitch fibers most important for bodybuilding outcomes.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
T3 therapy improves cardiac index by 0.24 L/min/m2 in adult cardiac surgery patients
Effect is population-specific — requires T3-deficient state from cardiac surgery. Not generalizable to euthyroid performance users. Does not apply to pediatric surgery, cardiac donors, heart failure, or AMI populations.
Combination T4+T3 raises Total T3 by 29.82 nmol/L and improves GHQ-28 general health scores (MD -2.89) vs T4 monotherapy
T3 benefit requires a deficiency state. No significant difference found for heart rate, SHBG, lipid profile, or depression scores — QoL benefit is modest in RCT settings.
Regulated LT3 use associated with no increased risk of AF, HF, or stroke and reduced all-cause mortality (RR 0.70)
Likely reflects selection bias — sicker patients treated with T3. Mortality reduction is not evidence that T3 extends life in healthy individuals. Adverse events in case reports were almost exclusively from unregulated use or compounding errors.
Supraphysiologic T3 (8x normal fT3) produced no significant physiological response in healthy euthyroid subjects
Animal model with limited human translation. Consistent with community observation that T3's dramatic metabolic effects require T3-deficient or TSH-suppressed substrate state. Does not apply to performance users who intentionally create a suppressed thyroid state.
75 mcg/day T3 for 14 days raises Free T3 1.7-fold, increases RMR approximately 15%, and preferentially catabolizes type IIA muscle fibers
Editorial/practitioner synthesis, not a controlled trial. Derived from existing literature synthesis. Type IIA fiber selectivity makes T3 particularly destructive late in contest prep when these fibers are already depleted.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.